Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice

Over the past few decades, the clinical outcomes of patients with cancer have significantly improved mostly owing to the development of effective chemotherapeutic treatments. However, chronic health conditions such as bone mass loss and risk of fragility fractures caused by chemotherapy have also em...

書目詳細資料
發表在:	Bone Reports
Main Authors:	Takahiro Ishizaka, Keisuke Horiuchi, Shinya Kondo, Masashi Isaji, Takahiro Nakagawa, Masahiro Inoue, Hajime Rikitake, Eiko Taguchi, Michiro Susa, Masaki Yoda, Takeshi Ono, Yusuke Kozai, Kazuhiro Chiba
格式:	Article
語言:	英语
出版:	Elsevier 2023-06-01
主題:	Cancer treatment-induced bone loss Eribulin mesylate Osteoclast Bisphosphonate RANKL Osteoprotegerin
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2352187223000414

相似書籍

Eribulin mesylate exerts antitumor effects via CD103
由: Kazumasa Oya, et al.
出版: (2023-12-01)

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
由: Lan Chen, et al.
出版: (2024-05-01)

The Effects of Receptor Activator of NF-κB Ligand-Binding Peptides on Bone Resorption and Bone Formation
由: Fatma Rashed, et al.
出版: (2021-07-01)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
由: Jonathan Noujaim, et al.
出版: (2016-01-01)

Polylactic/polyglycolic acid copolymer is a good carrier for BMP-2 on bone regeneration?
由: Alexandre Ladeira Veloso dos Anjos, et al.
出版: (2017-05-01)

Polylactic/polyglycolic acid copolymer is a good carrier for BMP-2 on bone regeneration?
由: Alexandre Ladeira Veloso dos Anjos, et al.
出版: (2017-05-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
由: Edward Phillips, et al.
出版: (2022-03-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
由: Chan Kai-Ming, et al.
出版: (2011-07-01)

Protection against Osteoporosis by Fermented Mulberry Vinegar Supplementation via Inhibiting Osteoclastic Activity in Ovariectomized Rats and Osteoclastic Cells
由: Eun Jung Yim, et al.
出版: (2022-05-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
由: Koliou P, et al.
出版: (2018-02-01)

The association of bone turnover markers with pro- and anti-inflammatory adipokines in patients with gestational diabetes
由: Beata Telejko, et al.
出版: (2015-05-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
由: Hyemi Ko, et al.
出版: (2022-04-01)

Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study
由: Osama E. Amer, et al.
出版: (2022-07-01)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
由: Tetsu Hayashida, et al.
出版: (2018-06-01)

Functionalized calcium phosphate nanoparticles to direct osteoprotegerin to bone lesion sites in a medaka (Oryzias latipes) osteoporosis model
由: Nurgul Imangali, et al.
出版: (2023-02-01)

Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
由: Xiaole Peng, et al.
出版: (2024-03-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
由: Sarah S. Mougalian, et al.
出版: (2018-09-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
由: Soumita Poddar, et al.
出版: (2023-08-01)

Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
由: Miaomiao Zhang, et al.
出版: (2025-01-01)

Osteomesopyknosis associated with a novel ALOX5 variant that impacts the RANKL pathway
由: Jose L. Fernandez‐Luna, et al.
出版: (2024-05-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
由: Sonam Mittal, et al.
出版: (2023-09-01)

Unraveling the impact of blood RANKL and OPG levels on Alzheimer's disease: Independent of bone mineral density and inflammation
由: Xingzhi Guo, et al.
出版: (2025-01-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
由: Mana Azumi, et al.
出版: (2022-12-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
由: S. L. Plavinsky, et al.
出版: (2016-02-01)

EFFECT OF GOLIMUMAB ON IMMUNOLOGICAL MARKERS FOR BONE METABOLISM AND ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
由: L. A. Knyazeva, et al.
出版: (2018-07-01)

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
由: L. A. Tashireva, et al.
出版: (2022-01-01)

Wheat seedling extract and its constituents attenuate RANKL-induced differentiation and fusion of osteoclasts and bone resorption
由: HanGyeol Lee, et al.
出版: (2023-09-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
由: Sakura Iizumi, et al.
出版: (2017-12-01)

Eribulin in Heavily Pre-Treated Metastatic Breast Cancer: A Case Series
由: Andini Kartikasari, et al.
出版: (2025-04-01)

The association of osteoprotegerin and RANKL with osteoporosis: a systematic review with meta-analysis
由: Guanghao Chi, et al.
出版: (2023-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
由: Riham Eid, et al.
出版: (2023-06-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
由: E. I. Kovalenko, et al.
出版: (2021-12-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
由: Jean-David Fumet, et al.
出版: (2018-08-01)

Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
由: A. V. Sultanbaev, et al.
出版: (2023-04-01)

Critical signaling pathways in osteoclast differentiation and bone resorption: mechanisms and therapeutic implications for periprosthetic osteolysis
由: Liangzi Yin, et al.
出版: (2025-08-01)

Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
由: Herleeyana Meriyani, et al.
出版: (2025-02-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
由: Tremblay G, et al.
出版: (2016-09-01)

Commentary on “time-dependent selected reaction monitoring-based GC-MS/MS method for estimation of genotoxic impurities in a new antibacterial agent: alalevonadifloxin mesylate”
由: D. J. Snodin, et al.
出版: (2020-11-01)

EFFECT OF INFLIXIMAB ON PARAMETERS OF REMODELING OF ARTERIAL BLOODSTREAM, RANKL AND OSTEOPROTEGERIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS
由: Larisa Aleksandrovna Knyazeva, et al.
出版: (2014-02-01)

Diagnostic potential of salivary interleukin‐17, RANKL, and OPG to differentiate between periodontal health and disease and discriminate stable and unstable periodontitis: A case‐control study
由: Marwa A. Abdullameer, et al.
出版: (2023-02-01)